• Explore /
  • Poster
  • / CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).

CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).

Abstract Poster

Authors

E. Gabriela Chiorean

E. Gabriela Chiorean

University of Washington, Seattle, WA

E. Gabriela Chiorean , Daniel D. Von Hoff , Thomas J. Ervin , Francis P. Arena , Jeffrey R. Infante , Venu Gopal Bathini , Tina Evans Wood , Paul N. Mainwaring , Robert T. Muldoon , Philip R. Clingan , Volker Kunzmann , Ramesh K. Ramanathan , Josep Tabernero , David Goldstein , Amy Ko , Brian Lu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT00844649

Citation

J Clin Oncol 31, 2013 (suppl; abstr 4058^)

DOI

10.1200/jco.2013.31.15_suppl.4058

Abstract #

4058^

Poster Bd #

18D

Abstract Disclosures

Similar Posters

First Author: Malcolm J. Moore

First Author: Akihiro Ohba

First Author: David Goldstein

First Author: Guifang Guo